JayMLeeMD
Thoracic Surgery • Los Angeles, CAAdult General Thoracic Surgery, Minimally Invasive Thoracic Surgery, Pediatric Thoracic Surgery, Thoracic Surgical Oncology
Thoracic Surgical Oncologist | Clinical Trials in Lung Cancer | Biotech
Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
UCLA Medical Center
10833 Le Conte Ave., 64-128 CHS
Los Angeles, CA 90095Phone+1 310-794-7333Fax+1 310-794-7333- Is this information wrong?
Summary
- Jay M. Lee, M.D., is the Surgical Director of the Thoracic Oncology Program, and Associate Professor of Surgery (Tenure Track) at the David Geffen School of Medicine at UCLA. He previously served as Chief, Division of Thoracic Surgery and Chief, Section of Thoracic Surgery for over a decade.
He received his medical degree from UCLA and training in General Surgery at Georgetown and Duke University Medical Centers. He completed a Thoracic Research Fellowship at Memorial Sloan Kettering Cancer Center and received Thoracic Surgery training at the Brigham and Women’s Hospital and Children’s Hospital Boston at Harvard Medical School.
Dr. Lee has published extensively in the field of thoracic oncology and has a funded research laboratory. His scientific effort has focused on translational trials involving investigator-initiated immunotherapy in human lung cancer and modulation of the immunosuppressive tumor microenvironment.
Dr. Lee is on the Steering Committee of several neoadjuvant or perioperative immunotherapy or targeted therapy trials in resectable non-small cell lung cancer (NSCLC) including LCMC3 (atezolizumab), CANOPY-N (canakinumab and/or pembrolizumab), NAUTIKA1 (alectinib, entrectinib, vemurafenib plus cobimetinib, pralsetinib, or stereotactic body radiation therapy plus atezolizumab),and GEOMETRY-N (capmatinib). Dr. Lee is also the Study Co-Chair for the Skyscraper-15 (phase 3 trial of adjuvant atezolzumab and tiragolumab). He is on the Scientific Advisory Committee for two Phase 3 Merck trials: Perioperative MK2870 (TROP2-ADC) and Adjvuant V940 (personalized mRNA cancer vaccine) with pembrolizumab. Dr. Lee is on the Executive Committee of the LCMC4/LEADER trial to define driver mutations in early stage NSCLC. Dr. Lee is an author on numerous peri-operative clinical trials including LCMC3 and IMPower 010 (adjuvant atezolizumab).
Dr. Lee is Board-certified by the American Board of Surgery (ABS) and the American Board of Thoracic Surgery (ABTS).
Education & Training
Brigham and Women's Hospital/Children's HospitalFellowship, Thoracic Surgery, 2004 - 2006
Duke University HospitalResidency, Surgery, 2001 - 2004
Memorial Sloan Kettering Cancer CenterPost-Doctoral Fellowship, Thoracic Service, 1999 - 2001
MedStar Health/Georgetown-Washington HospitalResidency, Surgery, 1997 - 1999
David Geffen School of Medicine at UCLAClass of 1997
Certifications & Licensure
DC State Medical License 1999 - Present
CA State Medical License 2006 - 2024
NC State Medical License 2001 - 2017
VA State Medical License 1998 - 2016
MA State Medical License 2004 - 2016- American Board of Surgery Surgery
- American Board of Thoracic Surgery Thoracic and Cardiac Surgery
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly
- Fellow (FACS) American College of Surgeons
- Super Doctor SuperDoctors.com
Clinical Trials
- Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Feb 26
- Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- 2 citationsAccelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonra...Trudy C Wu, Elaine Luterstein, Beth K Neilsen, Jonathan W Goldman, Edward B Garon, Jay M Lee, Carol Felix, Minsong Cao, Stephen E Tenn, Daniel A Low, Patrick A Kupelia...> ;JAMA Oncology. 2024 Mar 1
- 1 citationsArtificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.Dacic, S., Travis, W., Giltnane, J., Kos, F., Abel, J., Hilz, S., Fujimoto, J., Sholl, L., Ritter, J., Khalil, F., Liu, Y., Taylor-Weiner, A., Resnick, M., Yu, H., Hir...> ;Journal of Thoracic Oncology. 2023 Dec 7
- 1 citationsUnresectable Stage III NSCLC Should Not be Treated With Neoadjuvant Therapy and Re-Evaluated for Resection.Drew Moghanaki, Aaron Lisberg, Scott Oh, Jay Moon Lee> ;Journal of Thoracic Oncology. 2023 Sep 1
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- General Thoracic Surgical ClubMember
- International Association for the Study of Lung CancerMember
- Western Thoracic Surgical AssociationMember
- Society of University SurgeonsMember
- International Mesothelioma Interest GroupMember
- International Society for Minimally Invasive Cardiothoracic SurgeryMember
- International Thymic Malignancy Interest GroupMember
- Member
- Member
Hospital Affiliations
Ronald Reagan UCLA Medical CenterLos Angeles, California- UCLA Medical Center-Santa MonicaSanta Monica, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
